MEDIHONEY®
Antibacterial Dressing

80%* ACTIVE ANTIBACTERIAL MANUKA HONEY

MediHoney® Antibacterial Wound Gel application guide

MediHoney® Antibacterial Wound Gel consists of Medical Grade Manuka Honey combined with gelling agents derived from natural sources.

PREPARE
Assess wound and cleanse according to local protocol.

OPEN
Snap cap off.

APPLY
Apply a layer of Wound Gel to cover base of wound.

RE-SEAL
Use stopper to re-seal tube.

MEDIHONEY® WOUND GEL

Single patient use, Valid for 4 months from date of opening.

Apply an absorbent secondary dressing. Protect peri-wound area. Dressing changes will depend on condition of patient and wound exudate levels.

Dressing frequency will depend on condition of patient and exudate level. At dressing change, cleanse according to local protocol and reapply MediHoney Wound Gel dressing according to care plan.

Indications
- Acute and chronic wounds
- Infected and malodorous wounds
- Necrotic and sloughy wounds
- Pressure ulcers
- Surgical, donor sites, and recipient graft sites
- Leg ulcers (venous, arterial and mixed aetiology ulcers) and diabetic foot ulcers
- Superficial burns
- Superficial wounds such as cuts, scratches, and abrasions.

Contraindications
- Third degree burns
- Patients with a known sensitivity to honey.

i
- MediHoney has been safely used on patients of all ages
- Safe to use with diabetic patients[1-2]
- MediHoney has a low pH level of 3.5-4.5[8]
- Lowering the pH level has been associated with wound healing[3]
- Delivers Broad-spectrum antibacterial activity[4-7]

Product	Code	NHS	PIP
Wound gel 10gm	391	ELZ013	314-1207
Wound gel 20gm	395	ELZ507	314-1215

1. **White, R.,** MIMS Dermatology. 2006; 2(1): 40-42.
2. **Cadogan J.** The Diabetic Foot Journal; 2008; (1);43-45.
3. **Arthur Tarricone et al.** J Am Podiatr Med Assoc 1 November 2020; 110 (6): Article_13. doi: https://doi.org/10.7547/19-056
4. **Molan, Bee World.** 1992; 73, 5–28.
5. **Cooper et al.** 2002; J Burn Care Rehabil 23, 366–370
6. **Blair S.E. et al. Eur J** Clin Microbiol Infect Dis. 2009; 28, 1199–1208
7. **Maddocks et al.**, Microbiology, 2012.
8. **Boyar V. et al,** Journal of Perinatology, 2014, 34, 161–163; doi:10.1038/jp.2013.158.

Availability of these products might vary from a given country or region to another, as a result of specific local regulatory approval or clearance requirements for sale in such country or region.
- Non contractual document. The manufacturer reserves the right, without prior notice, to modify the products in order to improve their quality.
- Consult product labels and inserts for any indication, contraindications, hazards, warnings, precautions, and instructions for use.

Additional information for EMEA Customers only:
The product mentioned in this document is a CE class IIb device. Contact Integra should you need any additional information on devices classification. All the medical devices mentioned on this document are CE marked, unless specifically identified as "NOT CE MARKED".

For more information or to place an order, please contact:

International +33 (0)4 37 47 59 50 ▪ +33 (0)4 37 47 59 25 fax
Benelux +32 (0)2 257 4130 ▪ +32 (0)2 253 2466 fax
France +33 (0)4 37 47 59 10 ▪ +33 (0)4 37 47 59 29 fax
Switzerland +41 (0)22 721 23 00 ▪ +41 (0)22 721 23 99 fax
United Kingdom +44 (0)1 264 345 781 ▪ +44 (0)1 264 363 782 fax
integralife.eu

CE 1639
Derma Sciences, Inc.
104 Shorting Road
Toronto, Ontario M1S 3S4 ▪ Canada

EC REP
Integra LifeSciences Services (France)
Immeuble Séquoïa 2 ▪ 97 Allée Alexandre Borodine
Parc Technologique de la Porte des Alpes
69800 Saint Priest ▪ France

INTEGRA® LIMIT UNCERTAINTY

*by weight